Dimerix Opens Post-Trial Access to DMX-200 for FSGS Patients

Patients with focal segmental glomerulosclerosis gain continued access to investigational therapy, potentially delaying kidney function decline while awaiting regulatory decisions.

In the long struggle against rare kidney disease, a small biotech company has chosen not to abandon its trial participants at the threshold of uncertainty. Dimerix has opened post-trial access pathways for DMX-200, allowing patients with focal segmental glomerulosclerosis to continue receiving the investigational therapy through compassionate use and expanded access programs while the world awaits regulatory judgment. It is a gesture that acknowledges what clinical timelines often obscure: that behind every data point is a person whose kidneys are quietly failing, and for whom waiting is not a

Dimerix Opens Post-Trial Access to DMX-200 for FSGS Patients

Cobertura Relacionada

Recibe The Register en tu bandeja